ACS Medicinal Chemistry Letters · 2018 · 29 citations · 34 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryEnzymologyEnzyme DiscoveryEnzyme InhibitionEnzyme ScreeningStructure-activity Relationship AnalysisCarbonic Anhydrase InhibitorsCyclooxygenase InhibitorsCyclooxygenase IsoformsEnzyme FamiliesEnzyme Inhibition ScreeningInhibitor ScreeningMetabolic Enzyme InhibitionProtein Families
A novel series of of 4-[(3-phenyl-4-aryl-2,3-dihydro-1,3-thiazol-2-ylidene)amino]benzene-1-sulfonamides (EMAC10111a–g) was synthesized and assayed toward both human carbonic anhydrase isozymes I, II, IX, and XII and cyclooxygenase isoforms. The majority of these derivatives preferentially inhibit hCA isoforms II and XII and hCOX-2 isozyme, indicating that 2,3,4-trisubstituted 2,3-dihydrothiazoles are a promising scaffold for the inhibition of hCA isozymes and of hCOX-2 enzyme. The nature of the substituent at the dihydrothiazole ring position 4 influenced the activity and selectivity toward both enzyme families. EMAC10111g resulted as the best performing compound toward both enzyme families and exhibited preferential activity toward hCA XII and hCOX-2 isozymes.
34
Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents
Ravi G. Kurumbail, Anna M. Stevens, James K. Gierse et al. · Nature · 1996 · 1.9K citations
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
Santiago Zelenay, Annemarthe G. van der Veen, Jan P. Böttcher et al. · Cell · 2015 · 1.1K citations · Full text
Medicine, Immunology, Oncology +17